Codexis, Inc.
CDXS Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Insiders
Institutions
Government
Income
Balance Sheet
Cash Flow
CDXS Income Statement
CDXS Balance Sheet
CDXS Cash Flow
Recent trades of CDXS by members of U.S. Congress
| Politician | Type | Traded |
|---|---|---|
| Lamar Smith House / R | Purchase $1,001 - $15,000 | Apr. 06, 2018 |
CDXS Stock Insider Trading Activity
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
CDXS Stock Institutional Owners
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
CDXS Derivatives Institutional Owners
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by CDXS's directors and management
Government lobbying spending instances
-
$10,000 Jan 18, 2013 Issue: Energy/Nuclear
-
$13,200 Oct 15, 2012 Issue: Chemicals/Chemical Industry
-
$5,244 Jul 19, 2012 Issue: Fuel/Gas/Oil Chemicals/Chemical Industry
-
$19,500 Apr 18, 2012 Issue: Science/Technology
-
$13,100 Oct 18, 2011 Issue: Fuel/Gas/Oil
-
$17,000 Jul 20, 2011 Issue: Fuel/Gas/Oil
-
$60,000 Jan 17, 2011 Issue: Energy/Nuclear
-
$60,000 Oct 19, 2010 Issue: Energy/Nuclear
-
$60,000 Jul 17, 2010 Issue: Energy/Nuclear
-
$60,000 Apr 18, 2010 Issue: Energy/Nuclear
-
$60,000 Jan 16, 2010 Issue: Energy/Nuclear
-
$80,000 Oct 19, 2009 Issue: Energy/Nuclear Environment/Superfund
-
$50,000 Jul 18, 2009 Issue: Energy/Nuclear Environment/Superfund
Estimated quarterly lobbying spending
U.S. Patents
New patents grants
-
Patent Title: Engineered dna polymerase variants Oct. 29, 2024
-
Patent Title: T7 rna polymerase variants Oct. 29, 2024
-
Patent Title: Engineered pantothenate kinase variant enzymes Oct. 08, 2024
-
Patent Title: Biocatalysts for ezetimibe synthesis Oct. 08, 2024
-
Patent Title: Engineered purine nucleoside phosphorylase variant enzymes Oct. 08, 2024
-
Patent Title: Penicillin-g acylases Sep. 10, 2024
-
Patent Title: Engineered amylase variants Aug. 27, 2024
-
Patent Title: Lov-d acyltransferase mediated acylation Aug. 13, 2024
-
Patent Title: Ketoreductase polypeptides for the production of azetidinone Jul. 30, 2024
-
Patent Title: Ketoreductase polypeptides for the preparation of phenylephrine Jul. 09, 2024
-
Patent Title: Engineered dna polymerase variants Jun. 25, 2024
-
Patent Title: Peroxidase activity towards 10-acetyl-3,7-dihydroxyphenoxazine Jun. 18, 2024
-
Patent Title: Engineered galactose oxidase variant enzymes Jun. 18, 2024
-
Patent Title: Engineered imine reductases and methods for the reductive amination of ketone and amine compounds May. 21, 2024
-
Patent Title: Engineered acid alpha-glucosidase variants Apr. 30, 2024
-
Patent Title: Ketoreductase polypeptides for the production of (r)-3-hydroxythiolane Apr. 23, 2024
-
Patent Title: Penicillin-g acylases Apr. 23, 2024
-
Patent Title: Engineered protease variants Apr. 16, 2024
-
Patent Title: Variant lovd polypeptides and their uses Mar. 12, 2024
-
Patent Title: Engineered phenylalanine ammonia lyase polypeptides Feb. 27, 2024
-
Patent Title: Engineered adenylate kinase variant enzymes Feb. 27, 2024
-
Patent Title: Engineered acetate kinase variant enzymes Feb. 27, 2024
-
Patent Title: Engineered uridine phosphorylase variant enzymes Feb. 13, 2024
-
Patent Title: Engineered deoxyribose-phosphate aldolases Dec. 19, 2023
-
Patent Title: P450-bm3 variants with improved activity Nov. 07, 2023
-
Patent Title: Engineered imine reductases and methods for the reductive amination of ketone and amine compounds Oct. 31, 2023
-
Patent Title: Engineered phosphopentomutase variant enzymes Oct. 24, 2023
-
Patent Title: Engineered transaminase polypeptides Oct. 17, 2023
-
Patent Title: Engineered amylase variants Sep. 26, 2023
-
Patent Title: Engineered glycosyltransferases and steviol glycoside glucosylation methods Sep. 19, 2023
-
Patent Title: Ketoreductase polypeptides and polynucleotides Sep. 05, 2023
-
Patent Title: Engineered biocatalysts and methods for synthesizing chiral amines Aug. 22, 2023
-
Patent Title: Treatment of gluten intolerance and related conditions Aug. 15, 2023
-
Patent Title: Compositions and methods for treating gluten intolerance and disorders arising therefrom Aug. 15, 2023
-
Patent Title: Biocatalysts for the preparation of hydroxy substituted carbamates Aug. 01, 2023
-
Patent Title: Compositions and methods for treating gluten intolerance and disorders arising therefrom Jul. 18, 2023
-
Patent Title: Penicillin-g acylases May. 09, 2023
-
Patent Title: Vectors for expression of biocatalysts Apr. 25, 2023
-
Patent Title: Engineered imine reductases and methods for the reductive amination of ketone and amine compounds Apr. 04, 2023
-
Patent Title: Biocatalysts and methods for the synthesis of substituted lactams Mar. 07, 2023
-
Patent Title: Penicillin-g acylases Feb. 28, 2023
-
Patent Title: P450-bm3 variants with improved activity Feb. 28, 2023
-
Patent Title: Biocatalysts and methods for hydroxylation of chemical compounds Jan. 10, 2023
-
Patent Title: Transaminase polypeptides Jan. 03, 2023
-
Patent Title: Automated screening of enzyme variants Dec. 27, 2022
-
Patent Title: Engineered ketoreductase polypeptides Nov. 29, 2022
-
Patent Title: Human alpha-galactosidase variants Nov. 15, 2022
-
Patent Title: Ketoreductase polypeptides for the reduction of acetophenones Oct. 25, 2022
-
Patent Title: Engineered tyrosine ammonia lyase Oct. 18, 2022
-
Patent Title: Engineered galactose oxidase variant enzymes Oct. 11, 2022
Government Contracts
Federal grants, loans, and purchases
Government Contracts
Estimated quarterly amount awarded from public contracts
WallStreetBets
Number of mentions of CDXS in WallStreetBets Daily Discussion
CDXS News
Recent insights relating to CDXS
CNBC Recommendations
Recent picks made for CDXS stock on CNBC
Top ETF Holders
ETFs with the largest estimated holdings in CDXS
CDXS Stock Smart Score
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?
Sign Up to view CDXS Smart Score
Score Breakdown
Bull Case vs Bear Case
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
Bulls Say:
The Bulls Say summary highlights positive aspects of the stock.
Bears Say:
The Bears Say summary points out potential risks and negative aspects of the stock.
Show More